Article, Pharmaceuticals and Psychedelic therapy

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Article

Pharmaceuticals

Psychedelic therapy

One Person’s Journey from Celebrity Medical Model Advocate to Skeptic: An Interview with Rose Cartwright

Mad in America

NOVEMBER 6, 2024

You write that you worry about how psychedelics are getting co-opted by pharmaceutical industries. Cartwright: I do an exercise in my book where I speculate that if psychedelic therapy been available to my mother when she was at her worst, would it have been helpful? Dhar: That was my favorite part, the gentleness.

Trauma and the brain

Trauma and the brain Poverty and mental health Psychedelic therapy Childhood trauma

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Mad in America

AUGUST 14, 2024

L ykos Therapeutics experienced a double blow this week, with the FDA’s rejection of their proprietary MDMA-assisted therapy for PTSD and the retraction of three articles on MDMA’s supposed efficacy. Moreover, Lykos is a small company bringing it to market, one that emerged out of a psychedelic research nonprofit (MAPS).

Pharmaceuticals

Pharmaceuticals Nonprofits Psychedelic therapy

Mental Health Clinicians

One Person’s Journey from Celebrity Medical Model Advocate to Skeptic: An Interview with Rose Cartwright

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Stay Connected